Hopefully,. The technique also provides a powerful tool for determining the biological mechanisms of cancer may become resistant to certain treatments and to neutralize new therapies these mechanisms Hopefully, combination of such new therapies with other, established or investigational purposes, treatments can be improved of clinical trials of clinical trials to contribute. .. It is of use in prioritizing drug candidates for further systematic study of their properties before they are to be in clinical trials, he notes. This technique can show that the classical methods of studying candidate cancer drugs in laboratory conditions have overestimated the effectiveness of some agents, and underestimated others.
In the latter category, the researchers found a particular compound, active against myeloma tumor cells both in laboratory cultures and mice, for further investigation. Is in contact with healthy cells of the bone marrow – their usual location in patients. The compound prevented the myeloma cells of the reaction produced by the signals on the growth of bone marrow cells. With conventional techniques as drug candidates that would have gone completely unnoticed, Mitsiades observed.Add the earlier study which Ambati lab found previously immune to adverse reactions by siRNA, currently located in with FDA trials for many diseases as age-related Macular degeneration is and life-threatening virus infections.
Ambati laboratory also told last year in the New England Journal of Medicine that siRNA harm other types of cells, like of retinal pigmented epithelium, the age-related macular degeneration involved.